Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

BACKGROUND: Continuous, subcutaneous (SC) levodopa/carbidopa infusion with ND0612 is under development as a treatment for patients with Parkinson's disease (PD) and motor fluctuations. OBJECTIVE: Evaluate 1‐year safety data. METHODS: BeyoND is an open‐label study evaluating the long‐term safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Poewe, Werner, Stocchi, Fabrizio, Arkadir, David, Ebersbach, Georg, Ellenbogen, Aaron L., Giladi, Nir, Isaacson, Stuart H., Kieburtz, Karl, LeWitt, Peter, Olanow, C. Warren, Simuni, Tanya, Thomas, Astrid, Zlotogorski, Abraham, Adar, Liat, Case, Ryan, Oren, Sheila, Fuchs Orenbach, Shir, Rosenfeld, Olivia, Sasson, Nissim, Yardeni, Tami, Espay, Alberto J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Regular Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291977/
https://www.ncbi.nlm.nih.gov/pubmed/34496081
http://dx.doi.org/10.1002/mds.28758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291977/
https://www.ncbi.nlm.nih.gov/pubmed/34496081
http://dx.doi.org/10.1002/mds.28758

Ejemplares similares